Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines

Viruses

Volumn 8, Issue 7, 2016, Pages

  Kim, Shin Hee ^a   Samal, Siba K ^a  

^a UNIVERSITY OF MARYLAND   (United States)

Author keywords

Human vaccines; Newcastle disease virus; Vaccine vector; Veterinary vaccines

Indexed keywords

HN PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HYBRID PROTEIN; MATRIX PROTEIN; MESSENGER RNA; NUCLEOCAPSID PROTEIN; VACCINE; VETERINARY DRUG; VIRUS VECTOR; DRUG CARRIER; LIVE VACCINE; RECOMBINANT VACCINE;

AVIAN INFECTIOUS BRONCHITIS VIRUS; BORRELIA BURGDORFERI; BOVINE HERPESVIRUS 1; CANINE DISTEMPER VIRUS; EBOLAVIRUS; GENE NUMBER; HUMAN; HUMAN PARAINFLUENZA VIRUS 3; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNE RESPONSE; LARYNGOTRACHEOBRONCHITIS; NEWCASTLE DISEASE VIRUS; NIPAH VIRUS; NONHUMAN; NOROVIRUS; RABIES VIRUS; REVIEW; VACCINATION; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; GENE VECTOR; GENETICS; IMMUNOLOGY;

ANIMALS; DRUG CARRIERS; GENETIC VECTORS; HUMANS; NEWCASTLE DISEASE VIRUS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84977518046     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v8070183     Document Type: Review

References (54)

1. Morens, D. M.; Fauci, A. S. Emerging infectious diseases: Threats to human health and global stability. PLoS Pathog. 2013, 9, e1003467. [CrossRef] [PubMed].
2. Fauci, A. S.; Morens, D. M. The perpetual challenge of infectious diseases. N. Engl. J. Med. 2012, 366, 454-461. [CrossRef] [PubMed].
3. Belshe, R. B.; Edwards, K. M.; Vesikari, T.; Black, S. V.; Walker, R. E.; Hultquist, M.; Kemble, G.; Connor, E. M.; CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 2007, 356, 685-696. [CrossRef] [PubMed].
4. Bukreyev, A.; Collins, P. L. Newcastle disease virus as a vaccine vector for humans. Curr. Opin. Mol. Ther. 2008, 10, 46-55. [PubMed].
5. Samal, S. K. Newcastle disease and related avian paramyxoviruses. In The Biology of Paramyxoviruses; Samal, S. K., Ed.; Caister Academic Press: Norfolk, UK, 2011; pp. 69-114.
6. Alexander, D. J. Newcastle disease and other avian paramyxoviruses. Rev. Sci. Tech. 2000, 19, 443-462. [PubMed].
7. Peeters, B. P. H.; de Leeuw, O. S.; Koch, G.; Gielkens, A. L. J. Rescue of Newcastle disease virus from cloned cDNA: Evidence that cleavability of the fusion protein is a major determinant for virulence. J. Virol. 1999, 73, 5001-5009. [PubMed].
8. Panda, A.; Huang, Z.; Elankumaran, S.; Rockemann, D. D.; Samal, S. K. Role of fusion protein cleavage site in the virulence of Newcastle disease virus. Microb. Pathog. 2004, 36, 1-10. [CrossRef] [PubMed].
9. Krishnamurthy, S.; Huang, Z.; Samal, S. K. Recovery of a virulent strain of Newcastle disease virus from cloned cDNA: Expression of a foreign gene results in growth retardation and attenuation. Virology 2000, 278, 168-182. [CrossRef] [PubMed].
10. Huang, Z.; Krisnamurthy, S.; Panda, A.; Samal, S. K. High-level expression of a foreign gene from the 3′ proximal first locus of a recombinant Newcastle disease virus. J. Gen. Virol. 2001, 82, 1729-1736. [CrossRef] [PubMed].
11. Paldurai, A.; Kim, S. H.; Nayak, B.; Xiao, S.; Collins, P. L.; Samal, S. K. Evaluation of the contributions of the individual viral genes to Newcastle disease virulence and pathogenesis. J. Virol. 2014, 88, 8579-8596. [CrossRef] [PubMed].
12. Xiao, S.; Nayak, B.; Samuel, A.; Paldurai, A.; Kanabagattebasavarajappa, M.; Collins, P. L.; Samal, S. K. Generation by reverse genetics of an effective, stable, live-attenuated Newcastle disease virus vaccine based on a currently circulating, highly virulent Indonesian strain. PLoS ONE 2012, 7, e52751. [CrossRef] [PubMed].
13. Nakaya, T.; Cros, J.; Park, M. S.; Nakaya, Y.; Zheng, H.; Sagrera, A.; Villar, E.; García-Sastre, A.; Palese, P. Recombinant Newcastle disease virus as a vaccine vector. J. Virol. 2001, 75, 11868-11873. [CrossRef] [PubMed].
14. Carnero, E.; Li, W.; Borderia, A. V.; Moltedo, B.; Moran, T.; García-Sastre, A. Optimization of human immunodeficiency virus Gag expression by Newcastle disease virus vectors for the induction of potent immune responses. J. Virol. 2009, 83, 584-597. [CrossRef] [PubMed].
15. Zhao, H.; Peeters, B. P. H. Recombinant Newcastle disease virus as a viral vector: Effect of genomic location of foreign gene on gene expression and virus replication. J. Gen. Virol. 2013, 84, 781-788. [CrossRef] [PubMed].
16. Bukreyev, A.; Skiadopoulos, M. H.; Murphy, B. R.; Collins, P. L. Nonsegmented negative-strand viruses as vaccine vectors. J. Virol. 2006, 80, 10293-10306. [CrossRef] [PubMed].
17. Bukreyev, A.; Huang, Z.; Yang, L.; Elankumaran, S.; Claire, M.; Murphy, B. R.; Samal, S. K.; Collins, P. L. Recombinant Newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J. Virol. 2005, 79, 13275-13284. [CrossRef] [PubMed].
18. Freeman, A. I.; Zakay-Rones, Z.; Gomori, J. M.; Linetsky, E.; Rasooly, L.; Greenbaum, E.; Rozenman-Yair, S.; Panet, A.; Libson, E.; Irving, C. S.; et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol. Ther. 2006, 13, 221-228. [CrossRef] [PubMed].
19. Bukreyev, A.; Rollin, P. E.; Tate, M. K.; Yang, L.; Zaki, S. R.; Shieh, W. J.; Murphy, B. R.; Collins, P. L.; Sanchez, A. Successful topical respiratory tract immunization of primates against Ebola virus. J. Virol. 2007, 81, 6379-6388. [CrossRef] [PubMed].
20. DiNapoli, J. M.; Kotelkin, A.; Yang, L.; Elankumaran, S.; Murphy, B. R.; Samal, S. K.; Collins, P. L.; Bukreyev, A. Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc. Natl. Acad. Sci. USA 2007, 104, 9788-9793. [CrossRef] [PubMed].
21. DiNapoli, J. M.; Yang, L.; Suguitan, A.; Elankumaran, S.; Dorward, D. W.; Murphy, B. R.; Samal, S. K.; Collins, P. L.; Bukreyev, A. Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus. J. Virol. 2007, 81, 11560-11568. [CrossRef] [PubMed].
22. DiNapoli, J. M.; Nayak, B.; Yang, L.; Finneyfrock, B. W.; Cook, A.; Andersen, H.; Torres-Velez, F.; Murphy, B. R.; Samal, S. K.; Collins, P. L.; et al. Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys. J. Virol. 2010, 84, 1489-1503. [CrossRef] [PubMed].
23. Dinapoli, J. M.; Yang, L.; Samal, S. K.; Murphy, B. R.; Collins, P. L.; Bukreyev, A. Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010, 29, 17-25. [CrossRef] [PubMed].
24. Ge, J.; Deng, G.; Wen, Z.; Tian, G.; Wang, Y.; Shi, J.; Wang, X.; Li, Y.; Hu, S.; Jiang, Y.; et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J. Virol. 2007, 81, 150-158. [CrossRef] [PubMed].
25. Kim, S. H.; Chen, S.; Jiang, X.; Green, K. Y.; Samal, S. K. Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice. J. Virol. 2014, 88, 9718-9727. [CrossRef] [PubMed].
26. Kim, S. H.; Chen, S.; Jiang, X.; Green, K. Y.; Samal, S. K. Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein. Virology 2015, 484, 163-169. [CrossRef] [PubMed].
27. Nakaya, Y.; Nakaya, T.; Park, M. S.; Cros, J.; Imanishi, J.; Palese, P.; García-Sastre, A. Induction of cellular immune responses to simian immunodeficiency virus Gag by two recombinant negative-strand RNA virus vectors. J. Virol. 2004, 78, 9366-9375. [CrossRef] [PubMed].
28. Khattar, S. K.; Samal, S.; Devico, A. L.; Collins, P. L.; Samal, S. K. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J. Virol. 2011, 85, 10529-10541. [CrossRef] [PubMed].
29. Khattar, S. K.; Manoharan, V.; Bhattarai, B.; LaBranche, C. C.; Montefiori, D. C.; Samal, S. K. Mucosal immunization with Newcastle disease virus vector coexpressing HIV-1 Env and Gag proteins elicits potent serum, mucosal, and cellular immune responses that protect against vaccinia virus Env and Gag challenges. mBio 2015, 6, e01005. [CrossRef] [PubMed].
30. Khattar, S. K.; Devico, A. L.; Labranche, C. C.; Panda, A.; Montefiori, D. C.; Samal, S. K. Enhanced immune responses to HIV-1 envelope elicited by a vaccine regimen consisting of priming with Newcastle disease virus expressing HIV gp160 and boosting with gp120 and SOSIP gp140 proteins. J. Virol. 2016, 90, 1682-1686. [CrossRef] [PubMed].
31. Martinez-Sobrido, L.; Gitiban, N.; Fernandez-Sesma, A.; Cros, J.; Mertz, S. E.; Jewell, N. A.; Hammond, S.; Flano, E.; Durbin, R. K.; Garcia-Sastre, A.; et al. Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J. Virol. 2006, 80, 1130-1139. [CrossRef] [PubMed].
32. Kong, D.; Wen, Z.; Su, H.; Ge, J.; Chen, W.; Wang, X.; Wu, C.; Yang, C.; Chen, H.; Bu, Z. Newcastle disease virus-vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs. Virology 2012, 432, 327-335. [CrossRef] [PubMed].
33. Xiao, S.; Kumar, M.; Yang, X.; Akkoyunlu, M.; Collins, P. L.; Samal, S. K.; Pal, U. A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen. Vaccine 2011, 29, 5294-5303. [CrossRef] [PubMed].
34. Hall, A. J.; Lopman, B. A.; Payne, D. C.; Patel, M. M.; Gastañaduy, P. A.; Vinjé, J.; Parashar, U. D. Norovirus disease in the United States. Emerg. Infect. Dis. 2013, 19, 1198-1205. [CrossRef] [PubMed].
35. Duan, Z.; Xu, H.; Ji, X.; Zhao, J. Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases. Future Microbiol. 2015, 10, 1307-1323. [CrossRef] [PubMed].
36. Huang, Z.; Elankumaran, S.; Yunus, A. S.; Samal, S. K. A recombinant Newcastle disease virus expressing VP2 protein of infectious Bursal disease virus protects against NDV and IBDV. J. Virol. 2004, 78, 10054-10063. [CrossRef] [PubMed].
37. Ge, J.; Wang, X.; Tian, M.; Gao, Y.; Wen, Z.; Yu, G.; Zhou, W.; Zu, S.; Bu, Z. Recombinant Newcastle disease viral vector expressing hemagglutinin or fusion of canine distemper virus is safe and immunogenic in minks. Vaccine 2015, 33, 2457-2462. [CrossRef] [PubMed].
38. Kanabagatte Basavarajappa, M.; Kumar, S.; Khattar, S. K.; Gebreluul, G. T.; Paldurai, A.; Samal, S. K. A recombinant Newcastle disease virus (NDV) expressing infectious laryngotracheitis virus (ILTV) surface glycoprotein D protects against highly virulent ILTV and NDV challenges in chickens. Vaccine 2014, 32, 3555-3563. [CrossRef] [PubMed].
39. Toro, H.; Zhao, W.; Breedlove, C.; Zhang, Z.; Yub, Q. Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge. Avian Dis. 2014, 58, 83-89. [CrossRef] [PubMed].
40. Kortekaas, J.; Dekker, A.; de Boer, S. M.; Weerdmeester, K.; Vloet, R. P.; de Wit, A. A.; Peeters, B. P.; Moormann, R. J. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 2010, 28, 2271-2276. [CrossRef] [PubMed].
41. Kortekaas, J.; de Boer, S. M.; Kant, J.; Vloet, R. P. M.; Antonis, A. F. G.; Moormann, R. J. M. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 2010, 28, 4394-4401. [CrossRef] [PubMed].
42. Khattar, S. K.; Collins, P. L.; Samal, S. K. Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1. Vaccine 2010, 28, 3159-3170. [CrossRef] [PubMed].
43. Ge, J.; Wang, X.; Tao, L.; Wen, Z.; Feng, N.; Yang, S.; Xia, X.; Yang, C.; Chen, H.; Bu, Z. Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats. J. Virol. 2011, 85, 8241-8252. [CrossRef] [PubMed].
44. Veits, J.; Wiesner, D.; Fuchs, W.; Hoffmann, B.; Granzow, H.; Starick, E.; Mundt, E.; Schirrmeier, H.; Mebatsion, T.; Mettenleiter, T. C.; et al. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc. Natl. Acad. Sci. USA 2006, 103, 8197-8202. [CrossRef] [PubMed].
45. Nayak, B.; Rout, S. N.; Kumar, S.; Khalil, M. S.; Fouda, M. M.; Ahmed, L. E.; Earhart, K. C.; Perez, D. R.; Collins, P. L.; Samal, S. K. Immunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses. PLoS ONE 2009, 4, e6509. [CrossRef] [PubMed].
46. Park, M. S.; Steel, J.; Garcia-Sastre, A.; Swayne, D.; Palese, P. Engineered viral vaccine constructs with dual specificity: Avian influenza and Newcastle disease. Proc. Natl. Acad. Sci. USA 2006, 103, 8203-8208. [CrossRef] [PubMed].
47. McGeoch, D. J.; Dolan, A.; Ralph, A. C. Toward a comprehensive phylogeny for mammalian and avian herpesviruses. J. Virol. 2000, 74, 10401-10406. [CrossRef] [PubMed].
48. Zhao, W.; Spatz, S.; Zhang, Z.; Wen, G.; Garcia, M.; Zsak, L.; Yu, Q. Newcastle disease virus (NDV) recombinants expressing infectious laryngotracheitis virus (ILTV) glycoproteins gB and gD protect chickens against ILTV and NDV challenges. J. Virol. 2014, 88, 8397-8406. [CrossRef] [PubMed].
49. Chu, V. C.; McElroy, L. J.; Chu, V.; Bauman, B. E.; Whittaker, G. R. The avian coronavirus infectious bronchitis virus undergoes direct low-pH-dependent fusion activation during entry into host cells. J. Virol. 2006, 80, 3180-3188. [CrossRef] [PubMed].
50. Pepin, M.; Bouloy, M.; Bird, B. H.; Kemp, A.; Paweska, J. Rift Valley fever virus (Bunyaviridae: Phlebovirus): An update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet. Res. 2010, 41, 61. [CrossRef] [PubMed].
51. OIE (World Organisation for Animal Health) Avian Influenza. Available online: http://www. oie. int/fileadmin/Home/eng/Health_standards/tahm/2. 03. 04_AI. pdf(2012) (accessed on 30 July 2013).
52. Treanor, J. J.; Campbell, J. D.; Zangwill, K. M.; Rowe, T.; Wolff, M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 2006, 354, 1343-1351. [CrossRef] [PubMed].
53. Nayak, B.; Kumar, S.; DiNapoli, J. M.; Paldurai, A.; Perez, D. R.; Collins, P. L.; Samal, S. K. Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunity. J. Virol. 2010, 84, 2408-2420. [CrossRef] [PubMed].
54. Kim, S. H.; Paldurai, A.; Xiao, S.; Collins, P. L.; Samal, S. K. Modified Newcastle disease virus vectors expressing the H5 hemagglutinin induce enhanced protection against highly pathogenic H5N1 avian influenza virus in chickens. Vaccine 2014, 32, 4428-4435. [CrossRef] [PubMed].